Visterra secured an additional $13 million in a Series A funding round from existing and new investors, bringing the total raised to $26 million. The biotech startup will use the money to advance VIS410, an antibody to prevent and treat influenza, into clinical development.
Gates Foundation joins $26M round for developer of flu drug
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan